[Correspondence] Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma – Authors' reply

Geoffrey Ku and David Ilson note that the rate of R0 resection in the ST03 trial is low at 62%. They suggest that based on these findings, neoadjuvant chemoradiotherapy—rather than chemotherapy—should be used before surgery for patients with resectable adenocarcinomas involving the oesophagus. Although we agree that attaining an R0 resection should be a primary aim when treating patients with operable gastroesophageal cancer, we do not agree with their conclusion. We would also like to clarify that the rate of R0 resection in patients undergoing surgery in ST03 was 75%, rather than 62% (the latter being based on all patients, including those who did not undergo surgery).

http://ift.tt/2oVbz0Z